Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis

Pathology oncology research: POR

Grzegorz Helbig¹ 

[1] Medical University of Silesia

关键词: Acute myeloid leukemia;    Autologous hematopoietic stem cell transplantation;    Relapse;    Outcome;   

DOI  :  10.1007/s12253-017-0266-7

学科分类：生理学与病理学

来源: Springer

【 摘 要 】

IntroductionAn intensive combined chemotherapy including anthracycline and cytarabine remains a mainstay of induction treatment for medically fit and younger (<60 years) patients with acute myeloid leukemia (AML) producing a complete remission (CR) rate ranges from 60% to 70% [1]. The continuation of post-remission therapy seems to be mandatory in order to prevent relapse which may occur in virtually all patients after CR achievement [2]. The optimal post-remission treatment is still a matter of debate and may include repeated cycles of high-dose cytarabine, autologous hematopoietic stem cell transplantation (AHSCT) and allogeneic hematopoietic stem cell transplantation (AlloHSCT). The choice of post-remission therapeutic strategy should be guided by several factors associated with disease (e.g. cytogenetics), patient (e.g. performance status) or transplant (e.g. donor availability). The strongest anti-leukemic effect is associated with AlloHSCT, however it is counterbalanced by high non-relapse treatment-related mortality [3].

【 授权许可】

CC BY